Literature DB >> 18465170

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials.

Shekoufeh Nikfar1, Roja Rahimi, Fatemeh Rahimi, Saeed Derakhshani, Mohammad Abdollahi.   

Abstract

PURPOSE: This study was designed to evaluate whether probiotics improve symptoms in patients with irritable bowel syndrome.
METHODS: PubMed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies that investigated the efficacy of probiotics in the management of irritable bowel syndrome. Clinical improvement was the key outcome of interest. Data were searched within the time period of 1966 through September 2007.
RESULTS: Eight randomized, placebo-controlled, clinical trials met our criteria and were included in the analysis. Pooling of eight trials for the outcome of clinical improvement yielded a significant relative risk of 1.22 (95 percent confidence interval, 1.07-1.4; P = 0.0042).
CONCLUSIONS: Probiotics may improve symptoms of irritable bowel syndrome and can be used as supplement to standard therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18465170     DOI: 10.1007/s10350-008-9335-z

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  36 in total

Review 1.  A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease.

Authors:  Roja Rahimi; Mohammad Reza Shams-Ardekani; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

2.  Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis.

Authors:  Mahsa Moeinian; Seyedeh Farnaz Ghasemi-Niri; Shilan Mozaffari; Amir Hossein Abdolghaffari; Maryam Baeeri; Mona Navaea-Nigjeh; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 4.  Herbal medicines for the management of irritable bowel syndrome: a comprehensive review.

Authors:  Roja Rahimi; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

5.  Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial.

Authors:  Kyungsun Han; Jinghwa Wang; Jae-Gu Seo; Hojun Kim
Journal:  J Gastroenterol       Date:  2016-05-13       Impact factor: 7.527

Review 6.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 7.  Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Authors:  Tina Didari; Shilan Mozaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

8.  Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome.

Authors:  Sonia Michail; Harshavardhan Kenche
Journal:  Probiotics Antimicrob Proteins       Date:  2011-03       Impact factor: 4.609

9.  Probiotic treatment of irritable bowel syndrome in children.

Authors:  U Martens; P Enck; E Zieseniss
Journal:  Ger Med Sci       Date:  2010-03-02

10.  The effects of maturation on the colonic microflora in infancy and childhood.

Authors:  P Enck; K Zimmermann; K Rusch; A Schwiertz; S Klosterhalfen; J S Frick
Journal:  Gastroenterol Res Pract       Date:  2009-09-16       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.